Article thumbnail
Location of Repository

Identification of novel antigens for the development of a vaccine to prevent sexually transmitted Chlamydia infections

By Celia Louise McNeilly

Abstract

Chlamydia trachomatis infections are among the most frequently reported causes of human sexually transmitted infection. In Australia, the reported rate of infection in 2004 reached 175 per 100,000 population, the highest rate since surveillance of the condition began in 1991. Severe adverse sequelae that commonly occur following progression of the infection from the lower to the upper genital tract include pelvic inflammatory disease, infertility and ectopic pregnancy. However the frequent prevalance of asymptomatic infection makes diagnosis and treatment often late and therefore ineffective against upper genital tract complications. Hence there is a great need to develop a vaccine to protect against the sexual transmission of C.trachomatis. Despite many years of research investigating potential vaccine strategies to prevent sexually transmitted C.trachomatis infections, there remains no commercially available C.trachomatis vaccine. Early research showed that the use of live, attenuated or inactivated whole Chlamydia as a vaccine was not a viable option due to adverse effects caused by immunopathogenic cellular components. The early human vaccine trials that utilized whole chlamydial cells and resulted in exacerbated disease when immunized individuals were re-exposed to Chlamydia have led to the investigation of chlamydial subunit components as potential vaccine antigens. The most widely investigated vaccine candidate antigen is the major outer membrane protein (MOMP) as it is known to be immunogenic and surface exposed. Much research using this antigen has been undertaken with the antigen being delivered as a protein, peptide or DNA, via many mucosal and systemic routes of immunization, and in combination with various vaccine adjuvants. However, at best only partial protection against a chlamydial genital tract infection has been achieved. Only a few alternative candidate antigens have been investigated as potential vaccine targets to protect against chlamydial infections. These include the outer membrane porin PorB, the large cysteine rich outer membrane protein Omp2 and the heat shock proteins DnaK and GroEL. Although other candidate antigens have been predicted in various models of chlamydial infection (Finco et al., 2005; Stemke-Hale et al., 2005; Li et al., 2006), few have been tested for their protective efficacy. The aim of this study was to use expression library immunization to screen the whole C.muridarum genome for novel vaccine candidates capable of protecting against a chlamydial genital tract infection. C.muridarum was selected as the disease model for chlamydial genital tract infection as it has similarities to C.trachomatis in pathogenesis, immune response to infection and gene content and order. Once protective antigens had been isolated from an expression library, these were screened individually for immunogenicity and protective efficacy in the C.muridarum model of infection. An expression library containing over 21,000 recombinant C.muridarum clones was constructed and divided into pools of clones. DNA was extracted from these pools and used to immunize mice through gene gun technology, delivering 1μg of DNA to the abdomen of mice. Following the immunization regime, mice were challenged intra-vaginally with live C.muridarum as this route of infection best resembles the natural route of infection that is responsible for the sexual transmission of C.trachomatis in humans. Four in vivo screens of the C.muridarum expression library, each time using reduced numbers of clones, resulted in the identification of seven novel vaccine antigens that conferred protection against a genital tract challenge infection in mice. These warrant further investigation as vaccine antigens in the development of a vaccine against C.trachomatis infection. The identified antigens include antigens not conventionally believed to be potential vaccine candidates such as hypothetical proteins and housekeeping genes, including a DNA gyrase subunit, TC0462, and the ATP-dependent Clp protease, ATP-binding subunit ClpC, TC0559. Other antigens identified were more traditional, surface exposed vaccine targets that have not been previously investigated as vaccine targets, including a novel outer membrane protein, TC0512, a polymorphic membrane protein, TC0693, and TC0850, a protein of the type three secretion system, a family of proteins that allow gram-negative bacteria to inject virulence related proteins into the cytoplasm of a host cell. All antigens were shown to be partially protective with the putative outer membrane protein TC0512 showing an overall reduction in chlamydial burden of 55% and other antigens showing overall reductions in chlamydial burden of 26 - 44%. These antigens were also either capable of stimulating an immune response, or predicted to contain epitopes that may stimulate strong immune responses and so warrant further investigation as vaccine antigens to protect against chlamydial genital tract infections. The results of this research demonstrate that it is possible to identify novel vaccine targets through screening an expression library in a disease model. This study has identified several novel vaccine targets that are partially-protective against a C.muridarum infection and that are thought to be capable of stimulating strong immune responses. These antigens have high homology with C.trachomatis sequences, indicating that they have potential as vaccine candidates capable of protecting against the serovars of C.trachomatis that cause sexually transmitted infections in humans. Although the protection observed in this study was only partial, the immunization strategy utilised only fragments of the genes, an immunization mechanism known to elicit Th2 type immune responses, and no adjuvant to enhance the immunogenicity of the antigens. Through different immunization routes and in conjunction with adjuvants that stimulate Th1 type immune responses, complete protection against chlamydial genital tract infections may be achieved

Topics: chlamydia trachomatis, human sexually transmitted infection, vaccines, antigens, major outer membrane protein, C.muridarum genome
Publisher: Queensland University of Technology
Year: 2006
OAI identifier: oai:eprints.qut.edu.au:16352

Suggested articles

Citations

  1. (2002a). "Oxidised mannan as a novel adjuvant inducing mucosal IgA production." Vaccine
  2. (2002b). "Oxidised mannan-listeriolysin O conjugates induce Th1/Th2 cytokine responses after intranasal immunisation."
  3. (2004). 4th meeting on Novel Adjuvants Currently in/close to Human Clinical Testing World Health Organization --organisation Mondiale de la Sante Fondation Merieux,
  4. (2002). A Chlamydia trachomatis-specific Th2 clone does not provide protection against a genital infection and displays reduced trafficking to the infected genital mucosa."
  5. (1984). A colposcopic and histological study of experimental chlamydial cervicitis in marmosets."
  6. (1981). A new animal model for the study of Chlamydia trachomatis genital infections: infection of mice with the agent of mouse pneumonitis."
  7. (2005). A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection."
  8. (1996). A recombinant Chlamydia trachomatis major outer membrane protein binds to heparan sulfate receptors on epithelial cells."
  9. (2001). A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines."
  10. (1993). A three-tiered view of the role of IgA in mucosal defense."
  11. (2003). Abrams
  12. (2004). Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A*0201 transgenic mice."
  13. (2005). Adjuvant and antigen delivery properties of virosomes."
  14. (1998). Allsopp
  15. (2003). Alving
  16. (1987). Analysis of the humoral immune response to chlamydial genital infection in guinea pigs."
  17. (1994). Analysis of the humoral response elicited in mice by a chimeric peptide representing variable segments I and IV of the major outer membrane protein of Chlamydia trachomatis."
  18. (1983). Animal models of chlamydial infection."
  19. (1982). Antigenic analysis of the major outer membrane protein of Chlamydia spp."
  20. (1986). Antigenic specificity of human antibody to chlamydia in trachoma and lymphogranuloma venereum."
  21. (1991). Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma."
  22. (2006). Australia's notifiable diseases status, 2004, annual report of the National Notifiable Diseases Surveillance System."
  23. (1990). Bacteroides lipopolysaccharides (LPS) induce anaphylactoid and lethal reactions in LPS-responsive and -nonresponsive mice primed with muramyl dipeptide."
  24. (2005). Bcipep: a database of B-cell epitopes."
  25. (1992). Biological properties and genetic analysis of the ompA locus in chlamydiae isolated from swine."
  26. (1995). CD4+ T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract."
  27. (1994). CD8+ T lymphocyte-mediated lysis of Chlamydia-infected L cells using an endogenous antigen pathway."
  28. (1999). Characterization of immune responses following intramuscular DNA immunization with the MOMP gene of Chlamydia trachomatis mouse pneumonitis strain."
  29. (1999). Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis."
  30. (1994). Chlamydia trachomatis antigens: role in immunity and pathogenesis."
  31. (1997). Chlamydia trachomatis genital tract infection of antibody-deficient gene knockout mice."
  32. (1991). Chlamydia trachomatis induces an inflammatory response in the male genital tract and is associated with altered semen quality."
  33. (2000). Chlamydia trachomatis infection as a risk factor for invasive cervical cancer."
  34. (2006). Chlamydia trachomatis persistence: an update."
  35. (1995). Chlamydia trachomatis seropositivity during pregnancy is associated with perinatal complications."
  36. (1999). Chlamydia trachomatis: impact on human reproduction."
  37. (2002). Chlamydia vaccines: strategies and status."
  38. (1995). Chlamydial urethritis in heterosexual men attending a genitourinary medicine clinic: prevalence, symptoms, condom usage and partner change."
  39. (1985). Chronic chlamydial genital infection in congenitally athymic nude mice."
  40. (2003). Clinical practice. Genital chlamydial infections."
  41. (2000). Collaborative multidisciplinary workshop report: progress toward a Chlamydia pneumoniae vaccine."
  42. (1999). Comparative genomes of Chlamydia pneumoniae and C. trachomatis."
  43. (1997). Comparison of Chlamydia psittaci from cats with upper respiratory tract disease by polymerase chain reaction analysis of the ompA gene."
  44. (1997). Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women."
  45. (2001). Conjunctivitis due to Chlamydophila felis (Chlamydia psittaci feline pneumonitis agent) acquired from a cat: case report with molecular characterization of isolates from the patient and cat."
  46. (2002). Construction and characterization of an experimental ISCOMS-based hepatitis B polypeptide vaccine."
  47. (2000). CpG DNA induces stronger immune responses with less toxicity than other adjuvants."
  48. (1999). CpG motifs as immune adjuvants."
  49. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation."
  50. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma."
  51. (2001). Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization."
  52. (2002). Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization."
  53. (2003). de la Fuente
  54. (1988). de la Maza
  55. (1997). de Souza
  56. (2002). Design and selection of vaccine adjuvants: animal models and human trials."
  57. (2003). Development of a leishmaniasis vaccine: the importance of MPL."
  58. (1994). Developments in mucosal influenza virus vaccines."
  59. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization."
  60. (1990). Direct gene transfer into mouse muscle in vivo."
  61. (2004). Disease Control and Prevention
  62. (2000). Disease outcome subsequent to primary and secondary urogenital infection with murine or human biovars of Chlamydia trachomatis."
  63. (1997). Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice."
  64. (1987). Distal tubal obstruction induced by repeated Chlamydia trachomatis salpingeal infections in pig-tailed macaques."
  65. (1987). Diversity of Chlamydia trachomatis major outer membrane protein genes."
  66. (2004). DNA immunization followed by a viral vector booster in a Chlamydia pneumoniae mouse model."
  67. (2003). DNA immunization with pgp3 gene of Chlamydia trachomatis inhibits the spread of chlamydial infection from the lower to the upper genital tract in C3H/HeN mice."
  68. (1997). DNA vaccination with the major outer-membrane protein gene induces acquired immunity to Chlamydia trachomatis (mouse pneumonitis) infection."
  69. (1993). DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations."
  70. (1997). DNA vaccines."
  71. (1995). DNA-mediated immunization and the energetic immune response to hepatitis B surface antigen."
  72. (1983). Effect of antithymocyte serum on the course of chlamydial genital infection in female guinea pigs."
  73. (1992). Effect of gamma interferon on resolution of murine chlamydial genital infection."
  74. (2002). Effect of monophosphoryl lipid A (MPL) on Thelper cells when administered as an adjuvant with pneumocococcalCRM197 conjugate vaccine in healthy toddlers."
  75. (1997). Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production."
  76. (1998). Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A."
  77. (2002). Evaluation of SIV library vaccines with genetic cytokines in a macaque challenge."
  78. (1980). Experimental epididymitis and urethritis in grivet monkeys provoked by Chlamydia trachomatis."
  79. (2005). Expression library immunization confers protection against Mycobacterium avium subsp. paratuberculosis infection."
  80. (2000). Expression library immunization protects mice against a challenge with virulent rodent malaria."
  81. (2005). Expression library immunization: a road map for discovery of vaccines against infectious diseases."
  82. (2002). Gebbers
  83. (1995). Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA."
  84. (1995). Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection."
  85. (2003). Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity."
  86. (1992). Genetic immunization is a simple method for eliciting an immune response."
  87. (1997). Genetic to genomic vaccination."
  88. (1998). Genetic vaccines: strategies for optimization."
  89. (1991). Genital chlamydial infections: epidemiology and reproductive sequelae."
  90. (2000). Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39."
  91. (1993). Heterologous protection against influenza by injection of DNA encoding a viral protein."
  92. (1983). Holmes
  93. (2001). Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs."
  94. (1999). Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant."
  95. (2001). Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition."
  96. (2002). Humoral immune responses to microbial infections in the genital tract."
  97. (1979). Humoral immunity in the resolution of genital infection in female guinea pigs infected with the agent of guinea pig inclusion conjunctivitis."
  98. (2003). Identification of a protective antigen of Coccidioides immitis by expression library immunization."
  99. (1999). Identification of immunoreactive proteins of Chlamydia trachomatis by Western blot analysis of a two-dimensional electrophoresis map with patient sera." Electrophoresis
  100. (2005). Identification of new potential vaccine candidates against Chlamydia pneumoniae by multiple screenings."
  101. (2000). Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library."
  102. (2004). Igietseme
  103. (1999). IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens."
  104. (2004). Immune response to the Chlamydia trachomatis outer membrane protein PorB." Vaccine
  105. (2000). Immunity to Chlamydia pneumoniae induced by vaccination with DNA vectors expressing a cytoplasmic protein (Hsp60) or outer membrane proteins (MOMP and Omp2)." Vaccine
  106. (1997). Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways."
  107. (2002). Immunity to murine chlamydial genital infection."
  108. (2005). Immunization of mice with Neisseria meningitidis serogroup B genomic expression libraries elicits functional antibodies and reduces the level of bacteremia in an infant rat infection model."
  109. (2005). Immunization of mice with YscF provides protection from Yersinia pestis infections."
  110. (1994). Immunoglobulin G antibodies in human vaginal secretions after parenteral vaccination."
  111. (1970). Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test."
  112. (1997). Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants."
  113. (2001). Improved vectors for expression library immunization--application to Mycoplasma hyopneumoniae infection in pigs." Vaccine
  114. (1997). In defense of mucosal surfaces. Regulation and manipulation of the mucosal immune system."
  115. (2000). In situ analysis of the evolution of the primary immune response in murine Chlamydia trachomatis genital tract infection."
  116. (1984). In vitro neutralization of Chlamydia trachomatis with monoclonal antibody to an epitope on the major outer membrane protein."
  117. (1993). Induction and assessment of immunity at enteromucosal surfaces in humans: implications for vaccine development."
  118. (1991). Induction of antibody response to Chlamydia trachomatis in the genital tract by oral immunization."
  119. (2000). Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes."
  120. (2003). Induction of specific T-cell responses, opsonizing antibodies, and protection against Plasmodium chabaudi adami infection in mice vaccinated with genomic expression libraries expressed in targeted and secretory DNA vectors."
  121. (1988). Induction of tumor necrosis factor, IFN-gamma, and acute lethality in mice by toxic and non-toxic forms of lipid A."
  122. (1993). Infection in the male reproductive tract. Impact, diagnosis and treatment in relation to male infertility."
  123. (1972). Infection of genital tract and transmission of ocular infection to newborns by the agent of guinea pig inclusion conjunctivitis."
  124. (1989). Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies."
  125. (2005). Initial results of enhanced surveillance for lymphogranuloma venereum (LGV) in England."
  126. (1996). Initial route of antigen administration alters the T-cell cytokine profile produced in response to the mouse pneumonitis biovar of Chlamydia trachomatis following genital infection."
  127. (1991). Interaction of chlamydiae and host cells in vitro."
  128. (1997). Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae."
  129. (2005). ISCOM-based vaccines: the second decade."
  130. (2001). Isolation and characterization of a mutant Chinese hamster ovary cell line that is resistant to Chlamydia trachomatis infection at a novel step in the attachment process."
  131. (1981). Isolation of a nontoxic lipid A fraction containing tumor regression activity."
  132. (2002). Lipopolysaccharide endotoxins."
  133. (1988). Lipopolysaccharide-induced non-specific resistance to systemic Escherichia coli infection in mice."
  134. (2003). Long-term protective immune response elicited by vaccination with an expression genomic library of Toxoplasma gondii."
  135. (2006). Lymphogranuloma venereum in human immunodeficiency virus-infected individuals in New York City."
  136. (1996). Macrophages ingest and are activated by bacterial DNA."
  137. (2001). Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection."
  138. (2002). Mechanisms of monophosphoryl lipid A augmentation of host responses to recombinant HagB from Porphyromonas gingivalis."
  139. (1996). MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice."
  140. (2003). MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile."
  141. (2004). Molecular cloning of the Chlamydophila abortus groEL gene and evaluation of its protective efficacy in a murine model by genetic vaccination."
  142. (1996). Molecular mechanism of T-cell control of Chlamydia in mice: role of nitric oxide in vivo."
  143. Monoclonal antibodies to Chlamydia trachomatis: antibody specificities and antigen characterization."
  144. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration."
  145. (2006). Mouse model of respiratory Chlamydia pneumoniae infection for a genomic screen of subunit vaccine candidates."
  146. (1984). Mucopurulent cervicitis--the ignored counterpart in women of urethritis in men."
  147. (2006). Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection."
  148. (1990). Muramic acid is not detectable in Chlamydia psittaci or Chlamydia trachomatis by gas chromatography-mass spectrometry."
  149. (2005). Neonatal chlamydial infections: prevention and treatment."
  150. (1985). Neutralization of Chlamydia trachomatis cell culture infection by serovar-specific monoclonal antibodies."
  151. (1990). New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases."
  152. (2003). Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells."
  153. (1966). Observations on guinea pig inclusion conjunctivitis agent."
  154. (2002). Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis."
  155. (2002). ORFFINDER: a vector for high-throughput gene identification."
  156. (2001). Organization
  157. (1995). Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses."
  158. (1992). Pathogenesis of endometritis and salpingitis in a guinea pig model of chlamydial genital infection."
  159. (2000). PCR-based detection of chlamydial infection in swine and subsequent PCR-coupled genotyping of chlamydial omp1-gene amplicons by DNA-hybridization, RFLPanalysis, and nucleotide sequence analysis."
  160. (2002). Peeling
  161. (1992). Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results."
  162. (1994). Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis."
  163. (2003). Powder and particle-mediated approaches for delivery of DNA and protein vaccines into the epidermis."
  164. (2005). PREDBALB/c: a system for the prediction of peptide binding to H2d molecules, a haplotype of the BALB/c mouse."
  165. (1982). Prematurity and perinatal mortality in pregnancies complicated by maternal Chlamydia trachomatis infections."
  166. (1986). Preterm labor associated with subclinical amniotic fluid infection and with bacterial vaginosis."
  167. (2000). Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses."
  168. (1981). Progesterone as a key factor in the development of a mouse model for genital-tract infection with Chlamydia trachomatis."
  169. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised doubleblind placebo-controlled multicentre phase II efficacy trial."
  170. (1992). Proposal of Chlamydia pecorum sp. nov. for Chlamydia strains derived from ruminants."
  171. (1996). Prospects for a vaccine against Chlamydia genital disease II. -- Immunity and vaccine development."
  172. (1992). Prospects for human mucosal vaccines."
  173. (1995). Protection against mycoplasma infection using expression-library immunization."
  174. (2002). Protection evaluation against Chlamydophila abortus challenge by DNA vaccination with a dnaKencoding plasmid in pregnant and non-pregnant mice."
  175. (1994). Protective cytotoxic T lymphocytes are induced during murine infection with Chlamydia trachomatis."
  176. (1995). Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection."
  177. (1987). Protective monoclonal antibodies recognize epitopes located on the major outer membrane protein of Chlamydia trachomatis."
  178. (1988). Protein synthesis early in the developmental cycle of Chlamydia psittaci."
  179. (1987). Psittacosis: diagnosis and management of severe pneumonia and multi organ failure."
  180. (1981). Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis."
  181. (2001). Radical changes to chlamydial taxonomy are not necessary just yet." Int J Syst Evol Microbiol 51(Pt 1): 249; author reply
  182. Rank (1996a). "Prospects for a vaccine against Chlamydia genital disease I. -- Microbiology and pathogenesis."
  183. Rank (1996b). "Prospects for a vaccine against Chlamydia genital disease I. -- Microbiology and pathogenesis."
  184. (1997). Repeated Chlamydia trachomatis infection of Macaca nemestrina fallopian tubes produces a Th1-like cytokine response associated with fibrosis and scarring."
  185. (1987). Restriction endonuclease analysis of DNA from two isolates of Chlamydia psittaci obtained from human abortions."
  186. (1974). Restriction of gene expression in B lymphocytes and their progeny.
  187. (1995). Role of CD8 T cells in primary Chlamydia infection."
  188. (2000). Role of Chlamydia trachomatis in epididymitis. Part I: Direct and serologic diagnosis."
  189. (1999). Role of gamma interferon in controlling murine chlamydial genital tract infection."
  190. (2001). Role of infection in Alzheimer's disease."
  191. (1989). Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages."
  192. (1998). Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice."
  193. (1998). Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system."
  194. (2000). Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults." Vaccine
  195. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine."
  196. (1986). Salpingitis in mice induced by human strains of Chlamydia trachomatis."
  197. (2005). Screening the whole genome of a pathogen in vivo for individual protective antigens."
  198. (1988). Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction."
  199. (1990). Severity of salpingitis in mice after primary and repeated inoculation with a human strain of Chlamydia trachomatis."
  200. (2005). Specific-pathogen-free pigs as an animal model for studying Chlamydia trachomatis genital infection."
  201. (2005). SseJ deacylase activity by Salmonella enterica serovar Typhimurium promotes virulence in mice."
  202. (2001). Structure and composition of the Shigella flexneri "needle complex", a part of its type III secreton."
  203. (1999). SYFPEITHI: database for MHC ligands and peptide motifs."
  204. (2002). Taking toll: lipid A mimetics as adjuvants and immunomodulators."
  205. (2001). The anti-idiotypic antibody to chlamydial glycolipid exoantigen (GLXA) protects mice against genital infection with a human biovar of Chlamydia trachomatis."
  206. (2001). The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism."
  207. (1998). The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children."
  208. (1995). The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland."
  209. (1967). The host spectrum of psittacosis-lymphogranuloma venereum (PL) agents."
  210. (1995). The immunobiology and immunopathology of chlamydial infections."
  211. (2005). The miniature pig as an animal model in biomedical research."
  212. (1992). The mucosal immune system: from fundamental concepts to vaccine development."
  213. (1986). The occurrence of chlamydial and gonococcal salpingitis during the menstrual cycle."
  214. (1978). The potential for vaccine against infection of the genital tract with Chlamydia trachomatis."
  215. (1993). The relationship of Chlamydia trachomatis infection and male infertility."
  216. (2000). The role of Toll-like receptors and MyD88 in innate immune responses."
  217. (1963). The Selective Occurence of Gamma-1a Globulins in Certain Body Fluids."
  218. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection."
  219. (2001). The use of CpG DNA as a mucosal vaccine adjuvant."
  220. (1973). Three new immunologic types of trachoma-inclusion conjunctivitis organisms."
  221. (2005). Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy."
  222. (2001). Trafficking of surface-linked and encapsulated liposomal antigens in macrophages: an immunocytochemical study."
  223. (2000). Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract."
  224. (2004). Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection."
  225. Transcutaneous immunization: T cell responses and boosting of existing immunity."
  226. (2006). Trends in clinical encounters for pelvic inflammatory disease and epididymitis in a national sample of Australian general practices."
  227. (1988). Two distinct forms of Chlamydia psittaci associated with disease and infertility in Phascolarctos cinereus (koala)."
  228. (1998). Type I interferonmediated stimulation of T cells by CpG DNA."
  229. (1982). Ultrastructural analysis of the effects of erythromycin on the morphology and developmental cycle of Chlamydia trachomatis HAR-13."
  230. (1990). Variation in virulence among oculogenital serovars of Chlamydia trachomatis in experimental genital tract infection."
  231. (1993). William s a n d D .
  232. (2005). World Health Organization
  233. (1997). Yersinia pestis--etiologic agent of plague."

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.